Claims for Patent: 9,345,717

Summary for Patent: 9,345,717

Title:	Method for improving drug treatments in mammals
Abstract:	An improved method for identifying the size, shape and duration of drug exposure necessary to improve drug treatment in a subject with a bacterial infection. In addition, an improved method for identification of new dosing strategies which optimize the probability of positive treatment outcomes in subjects using resistance inhibitory concentration (RIC), wherein the subject has a bacterial infection caused by a bacterium with a propensity for heteroresistance. Further, an improved method for decreasing the potential for on-therapy drug resistance by determining a patient's RIC prior to administration of fosfomycin treatment, wherein RIC is utilized to differentiate the parameter which is best related to the driver or index of fosfomycin efficacy for the resistant subpopulation present and the required inhibitory concentration of those mutants.
Inventor(s):	Paul G. Ambrose, Evelyn Ellis-Grosse
Assignee:	Meitheal Pharmaceuticals Inc
Application Number:	US14/497,022
Patent Claims:	1. A method of identifying the dosing regimen required to optimize the probability of positive treatment outcomes in a subject using resistance inhibitor concentration (RIC), the method comprising: a) obtaining a sample from a subject suffering from a bacterial infection; b) identifying the presence of bacteria in said sample; c) determining the RIC of fosfomycin required to inhibit “resistant” mutant subpopulations of bacteria identified in step b); d) utilizing the RIC determined in step c) to calculate optimum dosing interval over the first 24 hours to maximize the killing of bacteria present in said sample; and e) administering fosfomycin to a subject according to the optimum dosing interval determined in step d), wherein the bacterial density is effectively reduced and the fosfomycin-resistant subpopulation is inhibited. 2. The method of claim 1, wherein the bacterial infection is caused by bacteria selected from the group consisting of Acinetobacter spp., Campylobacter spp., Citrobacter spp., Enterobacter spp, Enterococcus faecalis, Escherichia coli, Haemophilus influenza, Klebsiella oxytoca, Klebsiella pneumonia, Neisseria meningitides, Neisseria gonorrhea, Pseudomonas aeruginosa, Proteus mirabilis, Proteus vulgaris, Providencia rettgeri, Salmonella spp., Serratia marcessans, Shigella spp., and Yersinia enterocolitica. 3. The method of claim 1, wherein the fosfomycin is administered to a subject in a dose ranging from 1.56 mg/kg to 400 mg/kg. 4. The method of claim 2, wherein the bacterial infection is an infection caused by Escherichia coli. 5. The method of claim 2, wherein the bacterial infection is an infection caused by Enterococcus faecalis. 6. The method of claim 1, wherein the subject is a mammal. 7. The method of claim 6, wherein the mammal is a human. 8. A method for decreasing on-therapy drug resistance using resistance inhibitor concentration (RIC), the method comprising: a) obtaining a sample from a subject suffering from a bacterial infection; b) identifying the presence of bacteria in said sample; c) determining the RIC of fosfomycin required to inhibit “resistant” mutant subpopulations of bacteria identified in step b); d) utilizing the RIC determined in step c) to calculate optimum dosing interval over the first 24 hours to maximize the killing of bacteria present in said sample; and e) administering fosfomycin to a subject according to the optimum dosing interval determined in step d), wherein the bacterial density is effectively reduced and the fosfomycin-resistant subpopulation is inhibited. 9. The method of claim 8, wherein the bacterial infection is caused by bacteria selected from the group consisting of Acinetobacter spp., Campylobacter spp., Citrobacter spp., Enterobacter spp, Enterococcus faecalis, Escherichia coli, Haemophilus influenza, Klebsiella oxytoca, Klebsiella pneumonia, Neisseria meningitides, Neisseria gonorrhea, Pseudomonas aeruginosa, Proteus mirabilis, Proteus vulgaris, Providencia rettgeri, Salmonella spp., Serratia marcessans, Shigella spp., and Yersinia enterocolitica. 10. The method of claim 8, wherein the fosfomycin is administered to a subject in a dose ranging from 1.56 mg/kg to 400 mg/kg. 11. The method of claim 9, wherein the bacterial infection is an infection caused by Escherichia coli. 12. The method of claim 9, wherein the bacterial infection is an infection caused by Enterococcus faecalis. 13. The method of claim 8, wherein the subject is a mammal. 14. The method of claim 13, wherein the mammal is a human. 15. A method for treating a subject with a bacterial infection using resistance inhibitor concentration (RIC), the method comprising: a) obtaining a sample from a subject suffering from a bacterial infection; b) identifying the presence of bacteria in said sample; c) determining the RIC of fosfomycin required to inhibit “resistant” mutant subpopulations of bacteria identified in step b); d) utilizing the RIC determined in step c) to calculate optimum dosing interval over the first 24 hours to maximize the killing of bacteria present in said sample; and e) administering fosfomycin to a subject according to the optimum dosing interval determined in step d), wherein the bacterial density is effectively reduced and the fosfomycin-resistant subpopulation is inhibited. 16. The method of claim 15, wherein the bacterial infection is caused by bacteria selected from the group consisting of Acinetobacter spp., Campylobacter spp., Citrobacter spp., Enterobacter spp, Enterococcus faecalis, Escherichia coli, Haemophilus influenza, Klebsiella oxytoca, Klebsiella pneumonia, Neisseria meningitides, Neisseria gonorrhea, Pseudomonas aeruginosa, Proteus mirabilis, Proteus vulgaris, Providencia rettgeri, Salmonella spp., Serratia marcessans, Shigella spp., and Yersinia enterocolitica. 17. The method of claim 15, wherein the fosfomycin is administered to a subject in a dose ranging from 1.56 mg/kg to 400 mg/kg. 18. The method of claim 15, wherein the subject is a mammal. 19. The method of claim 18, wherein the mammal is a human.